Duchenne musküler distrofi’de üst ekstremite dinamik egzersizinin solunum fonksiyonu ve yaşam kalitesi üzerine etkisi
Türk Fizyoterapi ve Rehabilitasyon Dergisi/Turkish Journal of Physiotherapy and Rehabilitation - Tập 25 - Trang 1-8 - 2014
Tóm tắt
The aim of this study was to investigate the effects of upper extremity dynamic exercise on respiratory function and quality of life in children with Duchenne Muscular Dystrophy (DMD). In this study, children who diagnosed DMD scored as Level 1 or 2 according to the Brooke Upper Extremity Functional Classification (BUEFC) were divided into study and control groups with coin toss method randomly. Demographic datas were recorded. Timed performance tests (standing from supine, T-Shirt wearing/removing), electronic respiratory muscle strength device and Pediatric Quality of Life-3.0 (PedsQL-3.0) Neuromuscular Module child/parent questionnaire were used for evaluation of upper extremity performances, peak expiratory flow (PEF) and health-related quality of life, respectively. Study group had trained in arm ergometer, 8 weeks, 3 days per week, mean 40 minutes. Control group was applied normal range of motion upper extremity exercises as home programme. Assessments were repeated after 8 weeks. 24 DMD children, 12 control and 12 study subjects, respectively with mean age 9.33±1.37 and 9.50±1.38 were evaluated. Statistically significant differences were found in favor of study group in standing from supine position and T-shirt wearing time after exercise program (p<0.05). Significant increase was found in PEF liter value in study group (p<0.01). There were positive, moderate correlation between PedsQL-child scores and PEF (r=0.590; p<0.05); negative, strong correlation between PEF and T-Shirt wearing time (r=-0.629; p<0.05). It was found that upper extremity dynamic exercise with arm ergometer increased respiratory function and showed positive effect on quality of life of children with DMD.
Tài liệu tham khảo
Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77-93.
Van Essen AJ, Busch HF, te Meerman GJ, ten Kate LP. Birth and population prevalence of Duchenne muscular dystrophy in The Netherlands. Hum Genet. 1992;88(3):258-66.
Drousiotou A, Ioannou P, Georgiou T, Mavrikiou E, Christopoulos G, Kyriakides T, et al. Neonatal screening for Duchenne muscular dystrophy: a novel semiquantitative application of the bioluminescence test for creatine kinase in a pilot national program in Cyprus. Genet Test. 1998;2(1):55-60.
Bradley D, Parsons E. Newborn screening for Duchenne muscular dystrophy. Semin Neonatol. 1998;3(1):27-34.
Emery AE. Population frequencies of inherited neuromuscular diseases-a world survey. Neuromuscul Disord. 1991;1(1):19-29.
Jansen M, de Groot IJ, van Alfen N, Geurts A. Physical training in boys with Duchenne Muscular Dystrophy: the protocol of the No Use is Disuse study. BMC Pediatr. 2010;10:55.
Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51(6):919-28.
Kanagawa M, Toda T. The genetic and molecular basis of muscular dystrophy: roles of cell-matrix linkage in the pathogenesis. J Hum Genet. 2006;51(11):915-26.
Bartels B, Pangalila RF, Bergen MP, Cobben NA, Stam HJ, Roebroeck ME. Upper limb function in adults with Duchenne muscular dystrophy. J Rehabil Med. 2011;43(9):770-5.
Manzur AY, Muntoni F. Diagnosis and new treatments in muscular dystrophies. J Neurol Neurosurg Psychiatry. 2009;80(7):706-14.
Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. Neurol India. 2008;56(3):236-47.
Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord. 2006;16(4):249-55.
Roland EH. Muscular dystrophy. Pediatr Rev. 2000;21(7):233-7.
Phillips MF, Quinlivan RC, Edwards RH, Calverley PM. Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy. Am J Respir Crit Care Med. 2001;164(12):2191-4.
Rideau Y, Jankowski LW, Grellet J. Respiratory function in the muscular dystrophies. Muscle Nerve. 1981;4(2):155-64.
Bushby K, Bourke J, Bullock R, Eagle M, Gibson M, Quinby J. The multidisciplinary management of Duchenne muscular dystrophy. Current Paediatrics. 2005;15:292–300.
Bothwell JE, Dooley JM, Gordon KE, MacAuley A, Camfield PR, MacSween J. Duchenne muscular dystrophy–parental perceptions. Clin Pediatr (Phila). 2002;41(2):105-9.
Karaduman A, Yılmaz Ö, Tüzün EH, Günel MK, Aras B, Mutlu A, et al. A comparison of quality of life in children with cerebral palsy and neuromuscular diseases. Fizyoterapi Rehabilitasyon. 2010;21(1):3–10.
Rodillo E, Noble-Jamieson CM, Aber V, Heckmatt JZ, Muntoni F, Dubowitz V. Respiratory muscle training in Duchenne muscular dystrophy. Arch Dis Child. 1989;64(5):736–8.
Aboussouan LS. Mechanisms of exercise limitation and pulmonary rehabilitation for patients with neuromuscular disease. Chron Respir Dis. 2009;6(4):231–49.
Baiardini I, Minetti C, Bonifacino S, Porcu A, Klersy C, Petralia P, et al. Quality of life in Duchenne muscular dystrophy: the subjective impact on children and parents. J Child Neurol. 2011;26(6):707–13.
Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981;4(3):186–97.
Ingemar SJ, Merkies AB, Faber CG. Outcome measures in Duchenne muscular dystrophy: Are we ready fort he new therapeutic era? Neuromuscul Disord. 2009;19:447.
Moxley RT, Functional testing. Muscle Nerve. 1990;13:26–9.
Uneri ÖS, Ağaoğlu B, Coşkun A, Memik NC. Validity and reliability of Pediatric Quality of Life Inventory for the 2-to4-year-old and 5-to7-year old Turkish children. Qual Life Res. 2008;17:307–15.
Davis SE, Hynan LS, Limbers CA, Andersen CM, Greene MC, Varni JW, et al. The PedsQL in pediatric patients with Duchenne muscular dystrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory Neuromuscular Module and Generic Core Scales. J Clin Neuromuscul Dis. 2010;11(3):97-109.
Hayran M, Hayran M. Sağlık Araştırmaları için Temel İstatistik. Ankara: Art Ofset Matbaacılık Yayıncılık Organizasyon Ltd. Şti; 2011.
Buchanan DC, LaBarbera CJ, Roelofs R, Olson W. Reactions of families to children with Duchenne muscular dystrophy. Gen Hosp Psychiatry. 1979;1(3):262-9.
Abi Daoud MS, Dooley JM, Gordon KE. Depression in parents of children with Duchenne muscular dystrophy. Pediatr Neurol. 2004;31(1):16-9.
Nereo N, Fee RJ, Hinton VJ. Parental stress in mothers of boys with Duchenne muscular dystrophy. J Pediatr Psychol. 2003;28(7):473-84.
Chen JY, Chen SS, Jong YJ, Yang YH, Chang YY. A comparison of the stress and coping strategies between the parents of children with Duchenne muscular dystrophy and children with a fever. J Pediatr Nurs. 2002;17(5):369-79.
Eiser C, Morse R. A review of measures of quality of life for children with chronic illness. Arch Dis Child. 2001;84(3):205-11.
Grootenhuis MA, de Boone J, van der Kooi AJ. Living with muscular dystrophy: health related quality of life consequences for children and adults. Health Qual Life Outcomes. 2007;5:31.
Bray P, Bundy AC, Ryan MM, North KN, Everett A. Health-related quality of life in boys with Duchenne muscular dystrophy: agreement between parents and their sons. J Child Neurol. 2010;25(10):1188-94.
Ansved T. Muscular dystrophies: influence of physical conditioning on the disease evolution. Curr Opin Clin Nutr Metab Care. 2003;6:435–9.
Bar-Or O. Role of exercise in the assessment and management of neuromuscular diseases in children. Med Sci Sports Exerc. 1996;28:421–7.
Lovering RM, Porter NC, Bloch RJ. The muscular dystrophies: from genes to therapies. Phys Ther. 2005;85(12):1372-88.
Grange RW, Call JA. Recommendations to define exercise prescription for duchenne muscular dystrophy. Exerc Sport Sci Rev. 2007;35(1):12-7.